Fra­zier backs MavuPhar­ma’s $20M round, brings in heavy­weight ex­ecs to lead

Ven­ture part­ners at Fra­zier have put to­geth­er a dream team from their ex­ec­u­tive rolodex to a lead a new start­up called MavuPhar­ma. The new ven­ture is un­wrap­ping a $20 mil­lion Se­ries A to­day, along with plans to de­vel­op an in­creas­ing­ly pop­u­lar path­way in on­col­o­gy.

The com­pa­ny’s founders and board mem­bers in­clude names you’ve like­ly seen be­fore — Bob Bal­tera, Rich Hey­man, Michael Gal­latin, and Greg Di­etsch. These guys are se­r­i­al life sci­ence founders, and they’ve all worked to­geth­er on past ven­tures. They al­so have ties to Fra­zier Health­care Part­ners, which led the round.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER